Todd R. Daviau, Ph.D., MBA

President and CEO

Todd Daviau, an accomplished scientific leader, brings almost 30 years of pharmaceutical experience and knowledge to CoreRx, as well as being one of principal founders.

Prior to founding CoreRx, he served as Director of the Analytical and Pre-Formulation Laboratory for MDS Pharma Services in Tampa, FL. In this role, he directed the analytical group of over 20 scientists responsible for all the analytical, stability, and pre-formulation activities in support of over 75 stability, formulation and/or manufacturing projects.

Dr. Daviau was also a strategic analytical team member with Nova Pharmaceuticals (later Guilford Pharmaceuticals), and involved in a number of NDA programs, including the development of Gliadel®.

Todd is acknowledged as a creative leader focused on advancing projects with experience in multiple therapeutic areas. He is an expert in optimizing the drug discovery process through optimal resource allocation, process improvements and using scientific acumen to resolve complex project related issues. Todd brings a breadth of pharmaceutical experience, from drug discovery through research and development, analytical (R&D and QC.) and management experience in top-tier multinational pharmaceutical organizations. He is recognized as global, strategic thinker, with demonstrated ability to deliver pre-clinical and clinical candidates, within stringent timelines.

Dr. Daviau holds a bachelor’s degree in Marine Biology and Chemistry, a PhD in Natural Product Chemistry and an MBA in Business Management.

Frank Leo

Board Member

Frank Leo is a 40-year veteran of the pharmaceutical and healthcare industries having experience with publicly traded, private equity-backed, and start-up companies in the capacity of executive, investor, and advisor.

From 1999 to 2004, Mr. Leo served as President and Group President of Sterile Technologies and Life Sciences at Cardinal Health. He joined Cardinal Health following its acquisition of the sterile pharmaceutical contract manufacturing company Automatic Liquid Packing (ALP), where he held various senior level positions including Chief Operating Officer during his 16-year career.

At Cardinal Health he oversaw the growth of the biotechnology and life sciences group as well as managed the entire R&D technology platforms, which was later spun out to form Catalent Inc. Mr. Leo left Cardinal Health in 2004 but continued to serve as a retained advisor through 2005.

Mr. Leo joined (Private Equity Backed) Morton Grove Pharmaceuticals where he served as CEO from 2006 to 2007, overseeing its sale for its owners in 2007. Mr. Leo served as a Board Member of Gala Biotech, Rx Elite, Monogen, GeneraMedix, Azurity (NovaQuest Capital) and Capsugel (KKR), Leiters Pharma (HIG, SV LifeSciences, Frasier Health)

Mr. Leo is a serial entrepreneur, having been involved in business value creation and start-ups in the medical device, sterile drug, biotechnology and healthcare technology spaces.

Nailesh Bhatt

Board Member

With more than twenty years of pharmaceutical industry experience, Nailesh A. Bhatt brings a unique global perspective, valuable expertise, and a robust network to the Board of CoreRx.

A serial entrepreneur, Mr. Bhatt is Managing Director of Proximare – a strategic advisory firm that develops growth strategies for companies in the pharmaceutical and healthcare industries, including strategy development, licensing, mergers, acquisitions, and joint ventures. Proximare clients include large pharma, generics, CROs, CMOs, wholesalers, distributors, PBMs, payers, retailers, GPOs, and private equity groups. Proximare has successfully completed multiple M&A transactions, including cross-border deals. While at Proximare, Mr. Bhatt also launched Proximare Life Sciences Fund to invest in innovative biosimilars and emerging companies.

In addition, Mr. Bhatt is Founder and CEO of VGYAAN Pharmaceuticals which is focused on developing and commercializing clinically critical drugs.

Previously, Mr. Bhatt was the founder of with presence in the US, India, and Japan. Before that, Mr. Bhatt worked in increasing roles and responsibilities at Arthur Andersen, SEPPIC, and Sidmak Laboratories.

In addition to CoreRx, Mr. Bhatt serves as a Member of the Board of Directors of Azurity Pharmaceuticals, Sonnet BioTherapeutics (NASDAQ: SONN), and VGYAAN Pharmaceuticals.

Mr. Bhatt is a sought-after speaker at various industry conferences and has presented at the India Economic Summit organized by the World Economic Forum, the Federal Trade Commission, DCAT, and more.

Jeff Edwards

Board Member

Jeff Edwards has over 20 years of investment experience and is a Founder and Investment Committee Member of NovaQuest Private Equity.  He is responsible for the day-to-day management of NovaQuest Private Equity and transaction origination.  He currently sits on the boards of Azurity Pharmaceuticals, Inc., Catalyst Clinical Research, LLC and CoreRx, Inc.  Prior to joining NovaQuest, Mr. Edwards co-led the Principal Investment Private Equity program at the Teacher Retirement System of Texas, leading the efforts in the Healthcare and Industrial sectors across a variety of geographies. In that role, he was responsible for deal origination, as well as portfolio construction and portfolio management. Mr. Edwards’ previous experience also includes M&A advisory work for Raymond James Capital Markets, focusing on middle-market companies. Mr. Edwards also worked for State Street Global Markets (SSGM). His efforts were focused on private equity fund formation, portfolio management, and investment due diligence. Before moving back to the capital markets sector, he worked in finance and administrative roles in the healthcare industry with Carolinas HealthCare Systems and HCA, Inc. He started his career with the middle market investment bank RW Baird. Mr. Edwards received an MBA from the University of North Carolina at Chapel Hill, an MSF from Boston College, and a BA from the University of Tennessee at Knoxville.

Jim Gale

Founding Partner & Managing Director

James (Jim) Gale is the founding partner of Signet Healthcare Partners. Jim has over 30 years of healthcare investing and finance experience.

He is currently the Chairman of the Board of Bionpharma Inc. and Knight Therapeutics Inc. (TSX: GUD).  He also serves on the Board of Directors of Chr. Olesen Synthesis A/S, Hyloris SA , Leon Nanodrugs Gmbh, RK Pharma Inc and Pharmaceutics International (Pii). Prior portfolio company boards include Arbor Pharmaceuticals, Amarin Corporation, Cydex Inc  eResearch Technologies Inc., and Valera Pharmaceuticals.

Prior to founding Signet, Jim was head of principal investment activities and head of investment banking for Gruntal & Co., LLC. While at Gruntal, he made a number of investments including Andrx Corporation, Royce Laboratories (merged with Watson Pharmaceuticals), Lifecell Corporation, Neurocrine Biosciences, and BML Pharmaceuticals (acquired by Endo Pharmaceuticals).

Prior to joining Gruntal, he originated and managed private equity investments for the Home Insurance Co., Gruntal’s parent. Earlier in his career, Jim was a senior investment banker at E.F. Hutton & Co.

Jim received his Masters of Business Administration from the University of Chicago.

Ashton Poole

Board Member

Ashton Poole, Partner at NovaQuest Private Equity, has over 28 years of investment and transaction experience. He is responsible for transaction origination and execution, portfolio company value creation initiatives, investment policy, and investor relations. Mr. Poole is a member of the Private Equity investment committee and currently serves on the Board of Directors of Azurity Pharmaceuticals and CoreRx, two NovaQuest Private Equity portfolio companies.

Prior to joining NovaQuest, Mr. Poole was Chairman and Chief Executive Officer of Triangle Capital Corporation, a publicly traded business development company making private debt and equity investments in lower middle market companies across a variety of industries, including healthcare. In that role, he was responsible for setting corporate strategy and managing key functional areas of the company, including investment origination, underwriting, portfolio monitoring, capital raising, and investor relations. Mr. Poole served on the Management Committee, Investment Committee and Board of Directors of the company.

Mr. Poole’s previous experience also includes 19 years of corporate finance and M&A advisory work for Morgan Stanley, where he was a Managing Director in the investment banking division and worked out of the New York office. Mr. Poole started his career in strategy consulting, where he worked for 3 years in San Francisco at The MAC Group, which was subsequently acquired by Gemini Consulting.

Mr. Poole earned a BS in Business Administration from the University of North Carolina at Chapel Hill and a MBA from the J.L. Kellogg Graduate School of Management at Northwestern University.

Partner with us

When you’re ready to get expertise, flexibility, and reliability with your pharmaceutical formulation project, call us or fill out this form. We’ll be happy to answer your questions, provide a tour of our facilities, and get your project started today.